-
PROVIDERS
READ NOW
Minimal residual disease (MRD) testing: A practical guide for clinicians
-
LIFE SCIENCES
READ NOW
Q&A: Harnessing generative AI to refine clinical research & drug development
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
09/20/2022
Patient recruitment at the speed of science
Learn how Sermonix Pharmaceuticals partnered with Tempus and its TIME network of clinical sites to accelerate patient recruitment for a phase 2 study.
Authors
Sibel Blau, MD
President and CEO, Quality Cancer Care Alliance Network
Medical Director, Northwest Medical Specialties
Matthew Cooney, MD
Vice President, Therapeutic Development, Tempus
President and CEO, Quality Cancer Care Alliance Network
Medical Director, Northwest Medical Specialties
Matthew Cooney, MD
Vice President, Therapeutic Development, Tempus
-
08/29/2025Precision Medicine 2.0: The operating system for oncology R&D
This white paper addresses the persistent challenges in oncology R&D, demonstrating how precision medicine has evolved into a new paradigm built on systems-level understanding and AI-driven insights. Download for a comprehensive overview of Precision Medicine 2.0, its core scientific pillars, enabling technologies, and how R&D organizations can leverage this integrated approach to optimize their cancer research.
Read more -
08/15/2025Tempus’ data solutions for commercialization
Learn how our multimodal real-world data can help quantify new market opportunities, build your value story, and inform your market access strategy.
Read more -
08/15/2025Tempus’ data solutions for clinical development
Learn how our multimodal real-world data can help you optimize trial design, mitigate risk, and inform your companion diagnostic strategy.
Read more